As for common safety concerns, CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors showed different profiles in hepatotoxicity, gastrointestinal (GI) toxicity, and hyperglycemia. This evidence concerns the gene MTOR and Hyperglycemia.